Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Chronic Active Antibody Mediated Rejection
NCT03991780Phase 2Active, not recruiting
- Sponsor
- Imperial College London
- Start
- May 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in antibody mediated rejection (AMR), sponsored by Imperial College London. Started May 2019; status: active, not recruiting.
02
Drugs
fostamatinib
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03991780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991780.